DE69630639D1 - Rhodamin 123 Zusammensetzungen für Behandlung von Prostatakrebs - Google Patents

Rhodamin 123 Zusammensetzungen für Behandlung von Prostatakrebs

Info

Publication number
DE69630639D1
DE69630639D1 DE69630639T DE69630639T DE69630639D1 DE 69630639 D1 DE69630639 D1 DE 69630639D1 DE 69630639 T DE69630639 T DE 69630639T DE 69630639 T DE69630639 T DE 69630639T DE 69630639 D1 DE69630639 D1 DE 69630639D1
Authority
DE
Germany
Prior art keywords
prostate cancer
solution
rhodamine
water
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69630639T
Other languages
English (en)
Other versions
DE69630639T2 (de
Inventor
John Albert Arcadi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huntington Medical Research Institute
Original Assignee
Huntington Medical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huntington Medical Research Institute filed Critical Huntington Medical Research Institute
Application granted granted Critical
Publication of DE69630639D1 publication Critical patent/DE69630639D1/de
Publication of DE69630639T2 publication Critical patent/DE69630639T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69630639T 1995-08-16 1996-08-08 Rhodamin 123 Zusammensetzungen für Behandlung von Prostatakrebs Expired - Fee Related DE69630639T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51600495A 1995-08-16 1995-08-16
US516004 1995-08-16

Publications (2)

Publication Number Publication Date
DE69630639D1 true DE69630639D1 (de) 2003-12-18
DE69630639T2 DE69630639T2 (de) 2004-09-16

Family

ID=24053711

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630639T Expired - Fee Related DE69630639T2 (de) 1995-08-16 1996-08-08 Rhodamin 123 Zusammensetzungen für Behandlung von Prostatakrebs

Country Status (8)

Country Link
US (1) US7008961B1 (de)
EP (1) EP0761216B1 (de)
JP (1) JPH09110724A (de)
AT (1) ATE253908T1 (de)
AU (1) AU6207196A (de)
BR (1) BR9603454A (de)
CA (1) CA2183015A1 (de)
DE (1) DE69630639T2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay
WO2006024489A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Methods and compositions for the treatment of cell proliferation
WO2008115088A1 (fr) * 2007-03-16 2008-09-25 Evgeny Pavlovich Germanov Utilisation de rhodamine 6g en tant que médicament destiné au traitement de néoplasies malignes et d'amyloïdoses
WO2010120203A1 (ru) * 2009-04-14 2010-10-21 ГЕРМАНОВ, Евгений Павлович Применение органических красителей в качестве обезболивающих средств
US11474098B2 (en) 2017-12-22 2022-10-18 The Trustees Of Columbia University In The City Of New York Drug target for preventing pathologic calcium overload in cardiomyocytes and methods of screening for same
WO2023003497A1 (ru) * 2021-07-23 2023-01-26 Общество С Ограниченной Ответственностью "Валента-Интеллект" Соединения с лизосомотропной и противовирусной активностью
CN118121622A (zh) * 2024-01-29 2024-06-04 首都医科大学附属北京友谊医院 Se@SiO2-DTX在制备治疗前列腺癌或去势抵抗性前列腺癌产品中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
US5189029A (en) * 1990-04-23 1993-02-23 Bo-Dekk Ventures, Ltd. Indacene compounds and methods for using the same
NO923126L (no) 1991-08-13 1993-02-15 Fuji Photo Film Co Ltd Preparat og metode for behandling av canser
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
DE69630639T2 (de) 2004-09-16
EP0761216A1 (de) 1997-03-12
ATE253908T1 (de) 2003-11-15
MX9603412A (es) 1997-07-31
JPH09110724A (ja) 1997-04-28
AU6207196A (en) 1997-02-20
CA2183015A1 (en) 1997-02-17
BR9603454A (pt) 1998-05-12
EP0761216B1 (de) 2003-11-12
US7008961B1 (en) 2006-03-07

Similar Documents

Publication Publication Date Title
DE69215722D1 (de) Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
ES2191068T3 (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
ES2035259T3 (es) Compuesto absorbente.
BRPI0011640B8 (pt) ácidos aldônicos de oligossacarídeo e seu uso tópico
IT1170375B (it) Apparecchio che infonde insulina o glucosio nel soggetto diabetico sulla base di determinazioni di concentrazioni di glucosio ottenute senza bisogno di prelievi del sangue del paziente
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
DE3582439D1 (de) Mittel zur behandlung von herzerkrankungen.
ATE253908T1 (de) Rhodamin 123 zusammensetzungen für behandlung von prostatakrebs
ATE421319T1 (de) Mit s-nitrosothiol angereicherte erythrocyten und deren verwendung
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
DE69825887D1 (de) Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs
BE899809A (fr) Compositions pour usage cosmetique avec protection de la sante et du corps.
ATE99669T1 (de) N-2,3-butadienyl-tri-aminoalkanderivate.
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
KR900017599A (ko) 종양 치료용 약학 조성물
KR930702016A (ko) 골다공증 치료제
NO960347L (no) Anvendelse av benzydamid ved behandling av patologiske tilstander forårsaket av TNF
ATE36333T1 (de) Hydantoin enthaltende therapeutische mittel.
RU94024337A (ru) Антиметастатическое средство
IT1230175B (it) Diffusore di vapori profumati e medicali, realizzato mediante l'uso di elementi costruiti in metallo, preferibilmente inossidabile
RU97101420A (ru) Способ лечения тонзиллита
RU94016144A (ru) Средство для лечения больных болезнью рейтера

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee